Mitochondrial Dysfunction in Cardiovascular Diseases: Potential Targets for Treatment

Area of Science:

• Biomedical Science
• Cardiology
• Mitochondrial Biology

Background:

• Cardiovascular diseases (CVDs) represent a major global health burden, causing approximately one-third of all deaths worldwide.
• Mitochondrial dysfunction is a key contributor to the pathogenesis of various CVDs.
• Mitochondria generate adenosine triphosphate (ATP) via oxidative phosphorylation, producing reactive oxygen species (ROS) as a byproduct.

Purpose of the Study:

• To review the mechanisms underlying mitochondrial dysfunction in CVDs.
• To summarize the advancements in mitochondria-targeted therapies for cardiovascular conditions.
• To highlight potential cardiac mitochondrial targets for future research and clinical applications.

Main Methods:

• Literature review of studies on mitochondrial dysfunction in CVDs.
• Analysis of existing clinical drugs with known mitochondrial protective functions.
• Compilation of experimental and clinical data on novel cardiac mitochondrial targets.

Main Results:

• Excessive ROS production leads to mitochondrial dysfunction and cell death, contributing to CVD development.
• Established CVD medications like beta-blockers and ACE inhibitors/ARBs demonstrate mitochondrial protective effects.
• Numerous cardiac mitochondrial targets have exhibited cardioprotective effects in preclinical and clinical investigations.

Conclusions:

• Mitochondrial dysfunction is central to CVD pathogenesis.
• Mitochondria-targeted therapy presents a viable and evolving strategy for managing CVDs.
• Further exploration of cardiac mitochondrial targets holds significant potential for novel CVD treatments.